|
|
Vaccine Detail
|
gp100: ES209-217(210M) Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: gp100: ES209-217(210M) Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007490
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: gp100
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: gp100:209-217(210M) (NSC 683472) is an HLA-A2 restricted 9-mer (IMDQVPFSV) peptide from gp100 provided by Cancer Therapy Evaluation Program (CTEP) under Investigational New Drug Application BB6123 in vials containing 1 mg/mL of sterile water for injection with 0.1 N hydrogen chloride to adjust the pH (Sosman et al., 2008).
- Description: A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth (NCIT_C2763).
|
| Host Response |
|
|
| References |
NCIT_C2763: NCIT_C2763 [https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2763]
Sosman et al., 2008: Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26(14); 2292-2298. [PubMed: 18467720].
|
|
